awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33600521-E8CB1052-D8AE-4AFE-97E9-6B78FAEE0AD3
Q33600521-E8CB1052-D8AE-4AFE-97E9-6B78FAEE0AD3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33600521-E8CB1052-D8AE-4AFE-97E9-6B78FAEE0AD3
Phase I study of oral lenalidomide in patients with refractory metastatic cancer
P2860
Q33600521-E8CB1052-D8AE-4AFE-97E9-6B78FAEE0AD3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33600521-E8CB1052-D8AE-4AFE-97E9-6B78FAEE0AD3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0dadf6f56aaad735083ba265722242a86ea55054
P2860
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.